Showing 31 - 40 of 580
During the last thirty years health care expenditure (HCE) has been growing much more rapidly than GDP in all OECD countries posing increasing concern on the long-term sustainability of current trends. Against this background, we look at the determinants of HCE in European countries, explicitly...
Persistent link: https://www.econbiz.de/10005078989
We build a cumulative innovation model in which both success and failure provide valuable information for future research. To test this learning mechanism, we use a dataset covering outcomes of world-wide R&D projects in the pharmaceutical industry, and proxy knowledge flows with forward...
Persistent link: https://www.econbiz.de/10009391769
Persistent link: https://www.econbiz.de/10009404219
Persistent link: https://www.econbiz.de/10008316612
The pharmaceutical industry is a textbook example of a science based sector characterized by high R&D cost, uncertain and spillovers for which patent protection assures appropriability thus providing incentives for innovation. Indeed, Mansfield (1986) found that, absent patent protection, 60...
Persistent link: https://www.econbiz.de/10014216850
This paper investigates patterns of industrial dynamics and competition in the pharmaceutical industry, with particular reference to the consequences of patent expiry in different countries. We focus on the competition at the level of single chemical entities, distinguishing between original...
Persistent link: https://www.econbiz.de/10014048098
The prominent role played by patents within the pharmaceutical domain is unquestionable. In this paper, we focus on a relatively neglected implication of patents: the effect of patent-induced information disclosure on the dynamics of R&D and market competition. The study builds upon the...
Persistent link: https://www.econbiz.de/10004966691
We analyze the decline of R&D productivity in pharmaceuticals and its determinants. Since the molecular biology revolution, science has dramatically expanded the set of plausible therapeutic targets. However, innovation has become more difficult to achieve, and attrition rates of R&D projects...
Persistent link: https://www.econbiz.de/10008539680
The prominent role played by patents within the pharmaceutical domain is unquestionable. In this paper we take an unusual perspective and focus on a relatively neglected implication of patents: the effect of patent-induced information disclosure (of both successes and failures) on the dynamics...
Persistent link: https://www.econbiz.de/10005061430
During the last thirty years health care expenditure (HCE) has been growing much more rapidly than GDP in all OECD countries. Against this background, we look at the determinants of HCE growth in Europe, explicitly taking into account the role of income, ageing population, life habits,...
Persistent link: https://www.econbiz.de/10005061682